Introduction
Follitropin alfa and lutropin alfa are recombinant forms of follicle-stimulating hormone (FSH) and luteinizing hormone (LH), respectively. They are used in combination to treat infertility in both men and women. These hormones play a crucial role in reproductive health by stimulating ovarian follicle development in women and spermatogenesis in men.
Uses
Follitropin alfa and lutropin alfa are used in:
- Women with hypogonadotropic hypogonadism or hypopituitarism who are undergoing assisted reproductive technologies (ART), such as in vitro fertilization (IVF), to stimulate ovarian follicle development.
- Men with primary or secondary hypogonadism who are receiving treatment to stimulate sperm production.
| Brand Name | Pergoveris |
|---|---|
| Type | SC Injection |
| Weight | 150 IU (11 mcg) + 75 IU (3 mcg) |
| Generic | Follitropin Alfa + Lutropin Alfa |
| Manufacturer | Janata Traders |
| Available in | English বাংলা |
Mechanism of Action
Follitropin alfa, a recombinant FSH, promotes the growth and maturation of ovarian follicles by stimulating follicle-stimulating hormone receptors on the ovarian follicle cells. Lutropin alfa, a recombinant LH, supports the final maturation of follicles and triggers ovulation by acting on LH receptors. Together, these hormones work to regulate and enhance the reproductive cycle and fertility.
How Long Does It Take to Work?
The effects of follitropin alfa and lutropin alfa can vary depending on individual patient factors. Typically, ovarian response to these hormones can be observed within 7 to 14 days of starting treatment. The timing of ovulation or sperm production depends on the individual treatment plan and response to therapy. Regular monitoring through ultrasound and blood tests helps to assess treatment efficacy.
Absorption
Follitropin alfa and lutropin alfa are administered via subcutaneous or intramuscular injection. After injection, they are absorbed into the bloodstream, where they exhibit peak plasma concentrations within a few hours. The absorption rate may be influenced by the injection site and the specific formulation used.
Route of Elimination
Both follitropin alfa and lutropin alfa are metabolized in the liver and excreted primarily via the kidneys. The elimination involves breakdown by hepatic enzymes and subsequent renal excretion of the metabolites. The drug's pharmacokinetics may be affected by liver and kidney function.
Dosage
In LH and FSH deficient women (hypogonadotrophic hypogonadism), the objective of this injection therapy is to develop a single mature Graafian follicle from which the oocyte will be liberated after the administration of human chorionic gonadotrophin (hCG). This injection should be given as a course of daily injections. Since these patients are amenorrhoeic and have low endogenous oestrogen secretion, treatment can commence at any time.Treatment should be tailored to the individual patient's response as assessed by measuring follicle size by ultrasound and oestrogen response.
A recommended regimen commences with one vial of this injection daily. If less than one vial daily is used, the follicular response may be unsatisfactory because the amount of lutropin alfa may be insufficient.
If an FSH dose increase is deemed appropriate, dose adaptation should preferably be after 7-14 day intervals and preferably by 37.5-75 IU increments using a licensed follitropin alfa preparation. It may be acceptable to extend the duration of stimulation in any one cycle to up to 5 weeks.
When an optimal response is obtained, a single injection of 250 micrograms of r-hCG or 5,000 IU to 10,000 IU hCG should be administered 24-48 hours after the last this injection. The patient is recommended to have coitus on the day of, and on the day following, hCG administration. Alternatively, intrauterine insemination (IUI) may be performed.
Luteal phase support may be considered since lack of substances with luteotrophic activity (LH/hCG) after ovulation may lead to premature failure of the corpus luteum.
If an excessive response is obtained, treatment should be stopped and hCG withheld. Treatment should recommence in the next cycle at a dose of FSH lower than that of the previous cycle.
The dosage of follitropin alfa and lutropin alfa is individualized based on the patient's condition and response to therapy. Typical dosing regimens include:
- For women: Follitropin alfa is usually administered at doses ranging from 75 to 150 IU daily, often in combination with lutropin alfa at doses of 75 to 150 IU daily. Dosages may be adjusted based on ovarian response.
- For men: Follitropin alfa is administered at doses of 150 to 225 IU three times a week, combined with lutropin alfa at doses of 75 IU three times a week.
Administration
Follitropin alfa and lutropin alfa are administered via subcutaneous injections into the abdomen or thigh or intramuscular injections. Injection techniques should be reviewed and followed as instructed by a healthcare provider. Proper storage and preparation of the medication before administration are important for effectiveness.
Side Effects
Common side effects of follitropin alfa and lutropin alfa include:
- Injection site reactions (pain, redness, swelling)
- Headache
- Nausea
- Abdominal pain
- Fatigue
Toxicity
Overdose or excessive use of follitropin alfa and lutropin alfa can lead to overstimulation of the ovaries, resulting in ovarian hyperstimulation syndrome (OHSS), which is characterized by severe abdominal pain, nausea, and fluid retention. Management of toxicity involves discontinuing treatment and providing supportive care.
Precautions
Precautions include:
- Monitoring for signs of ovarian hyperstimulation syndrome (OHSS) and adjusting the dosage accordingly.
- Evaluating and managing potential allergic reactions.
- Assessing pre-existing conditions such as ovarian cysts or tumors that may be aggravated by treatment.
Interaction
Interactions with other medications are possible, especially with drugs that affect hormone levels or reproductive health. Inform healthcare providers about all medications being used, including over-the-counter drugs and supplements, to manage potential interactions effectively.
Disease Interaction
Consider potential interactions with:
- Pre-existing ovarian conditions (e.g., cysts or tumors), which may be exacerbated by treatment.
- Endocrine disorders that could affect hormone balance and treatment response.
Drug Interaction
Drug interactions may occur with:
- Other hormonal treatments: Adjustments may be required to avoid adverse effects or diminished efficacy.
- Medications affecting liver or kidney function: These can influence the metabolism and elimination of follitropin alfa and lutropin alfa.
Food Interactions
There are no significant food interactions with follitropin alfa and lutropin alfa. They can be administered with or without food. Patients should follow general dietary recommendations and consult their healthcare provider for specific guidance if needed.
Pregnancy Use
Follitropin alfa and lutropin alfa are used in fertility treatments and are not intended for use during pregnancy. The safety of these medications during pregnancy has not been established, and they should be used only under specific indications and guidance related to infertility treatment.
Lactation Use
The safety of follitropin alfa and lutropin alfa during lactation has not been well-studied. It is recommended to avoid breastfeeding while using these medications. Consult healthcare providers for guidance on managing fertility treatments and breastfeeding.
Acute Overdose
Acute overdose of follitropin alfa and lutropin alfa may lead to severe ovarian hyperstimulation syndrome (OHSS) and other complications. Immediate medical attention is necessary for overdose cases. Management includes supportive care and discontinuation of treatment.
Contraindication
Follitropin alfa and lutropin alfa are contraindicated in:
- Patients with known hypersensitivity to these hormones or their components.
- Patients with pre-existing ovarian tumors or other malignancies.
- Pregnant women or those with undiagnosed abnormal uterine bleeding.
Use Direction
Follow the prescribed dosage and administration instructions provided by a healthcare provider. Proper injection technique and adherence to the treatment schedule are important for achieving optimal results. Regular follow-up and monitoring are essential for managing treatment response and side effects.
Storage Conditions
Store follitropin alfa and lutropin alfa in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light and keep out of reach of children. Follow specific storage instructions provided by the manufacturer to maintain the stability and effectiveness of the medications.
Volume of Distribution
The volume of distribution for follitropin alfa and lutropin alfa is approximately 1 to 2 liters, indicating their distribution in the extracellular space and target tissues involved in reproductive function.
Half Life
The half-life of follitropin alfa is approximately 30 to 40 hours, while lutropin alfa has a similar half-life. This prolonged half-life supports the dosing schedule and allows for sustained hormonal effects.
Clearance
The clearance of follitropin alfa and lutropin alfa is primarily through renal and hepatic pathways. The drug clearance rates may be influenced by individual patient factors such as kidney and liver function.
See in details version Pergoveris SC Injection 150 IU (11 mcg) + 75 IU (3 mcg) also Pergoveris SC Injection 150 IU (11 mcg) + 75 IU (3 mcg) in bangla
